arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

EDAP TMS SA

FOCL
$4.22 ▼ -0.07 (-1.63%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
15 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

EDAP TMS SA faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $158.0M
Dividend Yield —
Revenue Growth 1.6%
Op. Margin -35.0% ↘
ROIC -67.0% ↘
FCF / Share $-0.44 ↘
Trailing P/E —
Price / Book 8.2x
FCF Yield —
Debt / Equity 1.24
info Valuation on last close. End-of-day price, Nov 5, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$70.53M
↑ +1.6% —
Net Income Profit after all expenses
$-29.25M
↓ -42.1% —
Operating Margin Operating profit as % of sales
-35.0%
↓ -9.3% 7th
FCF / Share Free cash flow per share
$-0.44
↓ -11.1% —
Long-Term Debt Long-term obligations
$18.02M
↑ +279.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
7
Returns ↓
5
Financial Health ↑
21
Cash Quality ↓
42

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 15 years · 17 quarters